BAY 1238097

Drug Profile

BAY 1238097

Alternative Names: BAY-1238097; BET inhibitor

Latest Information Update: 29 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Class Antineoplastics
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Preclinical Cancer; Haematological malignancies

Most Recent Events

  • 29 Nov 2016 Adverse events and pharmacokinetics data from a phase I trial in Solid tumours and lymphoma presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 07 Apr 2016 Pharmacodynamics data from preclinical and in vitro studies in Melanoma and Lung cancer presented at the 107th Annual Meeting of American Association for Cancer Research (AACR-2016) (3182732; 3182741)
  • 26 Feb 2016 Bayer terminates a phase I trial in Lymphoma and Solid tumours (Late-stage disease) in United States, United Kingdom, France, Finland, Germany and Switzerland (NCT02369029)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top